|Day Low/High||2.06 / 2.26|
|52 Wk Low/High||3.68 / 20.43|
Company to Host Conference Call Today, November 28, at 5:00 p.m. EST
Completion of Enrollment in Phase 2 Study of Cavosonstat for Treatment of Cystic Fibrosis Achieved During the Quarter
Here's a technical look at how to trade several under-$10 stocks that were making big moves to the upside recently.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Company on track to report results from the study in fourth quarter this year
Industry-leading patient reimbursement solution reaches milestone of 3 million transactions, totaling more than $200 million in patient reimbursements worldwide
N91115 is Currently in a Phase 2 Clinical Trial for Cystic Fibrosis, and Recently Received Orphan Drug Designation
Designation Marks Important Milestone in the Development and Regulatory Pathway for the First CFTR Stabilizer
Study Will Evaluate Efficacy and Safety of N91115, Data Expected in the Second Half of 2016
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
These stocks trading for less than $10 a share are within range of breaking out and trading higher from current levels.